Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
ABSTRAK
Latar Belakang: Penderita Diabetes Melitus (DM) mengalami peningkatan resiko fraktur akibat penurunan kualitas dan kekuatan tulang. Bone Mineral Densitometry tidak dapat menggambarkan fragilitas tulang pada pasien DM tipe 2 (DMT2) karena menunjukkan hasil yang normal atau meningkat. Penelitian sebelumnya menunjukkan terdapat penurunan penanda formasi tulang (P1NP) pada perempuan pramenopause dengan DMT2 dibandingkan dengan bukan DM. IGF-1 dan sclerostin adalah faktor yang mempengaruhi diferensiasi dan maturasi osteoblast dalam formasi tulang dan saat ini belum diketahui profilnya pada perempuan pramenopause dengan DM. Tujuan: Untuk mengetahui dan membandingkan kadar IGF-1 serum dan sclerostin serum perempuan pramenopause dengan DMT2 dan bukan DM. Metode: Studi potong lintang, dilakukan pada Agustus 2018 dan melibatkan 80 perempuan pramenopause yang terdiri dari 40 subjek DMT2 dan 40 bukan DM. Pemeriksaan IGF-1 serum dan Sclerostin serum dilakukan dengan metode enzymelinked immunosorbent assay (ELISA). Hasil penelitian: Median (rentang interkuartal) kadar IGF-1 serum pada pasien DMT2 lebih rendah tidak bermakna dibandingkan dengan kelompok bukan DM (40,6 (11-110) ng/ml vs 42,75 (10-65) ng/ml, p=0.900). Rerata kadar sclerostin serum pada kelompok DMT2 lebih tinggi bermakna dibandingkan kelompok bukan DM (132.05 (SB 41.54) ng/ml vs. 96.03 ng/ml (SB 43.66) (p<0.001). Kesimpulan: Tidak terdapat perbedaan kadar IGF-1 serum antara perempuan pramenopause DMT2 dan bukan DM. Terdapat perbedaan bermakna sclerostin serum antara perempuan pramenopause dengan DMT2 dan bukan DM.

---

ABSTRACT
Background: Diabetes mellitus (DM) patients are at increased risk for fracture due to the decrease in bone quality and strength. Bone Mineral Densitometry (BMD) measurement in T2DM cannot depict bone fragility (T2DM) because they are shown to be normal or increased results. Previous studies have shown a decrease in markers of bone formation (P1NP) in premenopausal women with T2DM compered non-DM. IGF-1 and sclerostin are factors that influence the differentiation and maturation of osteoblasts in bone formation and their profiles are not currently known in patients with premenopausal women with diabetes. Objective: To determine and compare serum IGF-1 and serum sclerostin levels between premenopausal women T2DM and non-DM. Method: A cross-sectional study was conducted in August 2018 and involved 80 premenopausal women consisting of 40 DMT2 and 40 non-DM subjects. Serum IGF-1 and serum sclerostin were examined using an enzyme-linked immunosorbent assay (ELISA) method. Results: Median (interquarter range) serum IGF-1 in T2DM is 40.6 ng/ml (11-110 ng/ml) vs. 42.75 ng/ml (10-65 ng/ml) in non-DM (p=0.900). Mean serum sclerostin level in T2DM is 132.05 ng/ml (SB 41.54 ng/ml) vs. 96.03 ng/ml (SB 43.66 ng/ml) in not DM (p<0.001). Conclusion: There was no difference in serum IGF-1 levels between premenopausal women with T2DM and non-DM. There were significant differences in serum sclerostin between premenopausal women with T2DM and non-DM.

Abstrak :
Osteoporosis is a metabolic bone disease and is characterized by low bone mass and microstructur deterioration of the bone which leads to increased risk of fracture. Biomarker of bone metabolism can be seen as beginning of bone loss and first detection before imbalanced bone turnover comes. Biomarker of bone formation as serum bone alkaline fosfatase, osteocalcin (OC), procollagen type I, and biomarker of bone resorption as urine pyridinoline (Pyd) and deoxypyridinoline (Dpd) crosslinks, hydroxyprolin. The simultanious examination of serum OC and urine Pyd or Dpd as a very good screening test for determination of bone imbalanced at the moment of the menopausal of the beginning of the pasca menopausal. Saliva as a potential diagnostic fluid for the assessment of osteoporosis biomarker concentrations. The study found elevated three classic warning signs for osteoporosis as OC, Dpd and II 6 in the saliva of sheep without ovaries, which were similar to the levels of signs found in their blood and urine. Expectations, that the test may become available within five years and one day the test may be able to be performed at home like pregnancy test. Osteoporosis biomarker in saliva suggested detected of bone mass density easier. Beside that can used as a metode of early diagnostic and as a monitor therapy that as salinity of the examinations of bone mass on radiology.